1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
1 citations
,
September 2015 Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
June 2026 in “Pharmaceutical Sciences and Research” Chemotherapy regimens were appropriate, but managing adverse effects like anemia and hair loss is crucial.
June 2026 in “International Journal of Drug Delivery Technology” Silver nanoparticles from Pogostemon benghalensis may effectively fight lung cancer cells.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
January 2024 in “Technology in Cancer Research & Treatment” Anti-angiogenic drugs do not worsen COVID-19 severity in lung cancer patients.
December 2023 in “Journal of Thoracic Disease” Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.
June 2023 in “Deleted Journal” The document lists research on Pemetrexed and Cisplatin for lung cancer but doesn't give a final conclusion.
October 2021 in “QJM: An International Journal of Medicine” The experiment successfully created a 3D model of a rat lung using a natural scaffold.
A 69-year-old smoker was wrongly diagnosed with lung cancer but actually had a rare lymphatic system disorder.
September 2017 in “Pure and Applied Biology” Chemotherapy and radiotherapy improved quality of life and reduced symptoms in lung cancer patients.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
42 citations
,
November 2002 in “The American journal of pathology” Distinct β-catenin patterns are linked to cell growth, not cell death, in lung cancer.
28 citations
,
September 2014 in “Journal of Clinical Oncology” Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.
19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
3 citations
,
October 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.
1 citations
,
December 2021 in “Tropical Journal of Pharmaceutical Research” Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
More research is needed to understand chemotherapy-induced hair loss and its phases.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.
45 citations
,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
2 citations
,
June 2020 in “Research Square (Research Square)” A prostate cancer drug can lower the levels of a protein that the coronavirus uses to enter lung cells.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
139 citations
,
December 2020 in “Cell Stem Cell” Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.
139 citations
,
February 2010 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Transplant success has improved with better immunosuppressive drugs and donor matching.
105 citations
,
February 2017 in “British Journal of Dermatology” Survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis need ongoing care for various long-term health problems.